ArticleFrontiers in pharmacology2026
Knowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of glucagon-like peptide-1 (GLP-1) receptor agonists has increased rapidly in Saudi Arabia for weight management and glycaemic control. However, concerns remain regarding inappropriate use, medication safety, and misconceptions surrounding these therapies. This study assessed the knowledge, attitudes, and practices (KAP) of GLP-1 receptor agonist users in Saudi Arabia and identified factors associated with these domains. Methods: A cross-sectional study was conducted among adult GLP-1 receptor agonist users in Saudi Arabia between December 2025 and March 2026. Eligible participants were aged ≥18 years and had used semaglutide, liraglutide, dulaglutide, or tirzepatide within the previous 12 months. Participants were recruited through purposive snowball sampling via social media platforms. Descriptive statistics and binary logistic regression were used to assess KAP levels and associated factors. Results: A total of 310 participants were included. The median age was 33 years (IQR: 16), and the median BMI was 33.9 kg/m Conclusion: GLP-1 receptor agonist users demonstrated generally favourable medication-use practices but suboptimal knowledge and attitudes. Higher knowledge was associated with more positive attitudes and better practices, highlighting the importance of patient education and healthcare professional counselling to support safe and informed use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.